Evidence map›Paper›PMID 39463792›Full record

ReviewFrontiers in neurology2024

Harnessing artificial intelligence for the diagnosis and treatment of neurological emergencies: a comprehensive review of recent advances and future directions.

Majd A AbuAlrob, Boulenouar Mesraoua

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Majd A AbuAlrobDepartment of Neurosciences, Hamad Medical Corporation, Doha, Qatar.
Boulenouar MesraouaDepartment of Neurosciences, Hamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) is rapidly transforming the landscape of neurology, offering innovative solutions for diagnosing and managing emergent neurological conditions such as stroke, traumatic brain injury, and acute spinal cord injury. This review critically examines the recent advancements in AI applications within the field of neurology, emphasizing both the potential and limitations of these technologies. While AI demonstrates remarkable accuracy and speed in diagnostic imaging, outcome prediction, and personalized treatment plans, its integration into clinical practice remains challenged by ethical concerns, infrastructural limitations, and the "black box" nature of many AI algorithms. The review highlights the current gaps in literature, particularly the limited research on AI's use in low-resource settings and its generalizability across diverse populations. Moreover, the review underscores the need for more longitudinal studies to assess the long-term efficacy of AI-driven interventions and calls for greater transparency in AI systems to enhance trust among clinicians. Future directions for AI in neurology emphasize the importance of interdisciplinary collaboration, regulatory oversight, and the development of equitable AI models that can benefit all patient populations. This review provides a balanced and comprehensive overview of AI's role in neurology, offering insights into both the opportunities and challenges that lie ahead.

Indexed as

AI in diagnosisAI in epilepsyartificial intelligenceneurologyneurology emergencies

Identifiers

PMID39463792
PMCPMC11502371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.